Summary
The analysis of volatile organic compounds (VOCs) in exhaled breath with nano sensors has great potential to transform healthcare, with accurate, inexpensive, real-time diagnostics. However, attempts to implement this strategy have failed to reach clinical deployment. Firstly, many efforts try to identify the complex mixture of VOCs associated with disease, which is a long and expensive process. Secondly, commercially available sensors require high operating temperatures and have low sensitivity to breath VOCs. NaNose Medical has overcome these limitations through DiaNose, an easy to use, hand-held diagnostics device with potential applicability in >20 different diseases. Instead of identifying individual VOCs, DiaNose deploys an array of patented cross-reactive sensors delivering a chemical signature of breath that can be classified as healthy or diseased through artificial intelligence. Our initial alpha prototype focuses on a key clinical indication: Non-Alcoholic Fatty Liver Disease (NAFLD): with a global prevalence of 30%, it is the leading cause of liver related morbidity, generating an annual burden in Europe of > €35 billion and a further €200 billion of societal costs. Crucially, NAFLD diagnostics present key limitations: liver biopsies are expensive, invasive and subject to sampling error, and non-invasive alternatives lack precision, are operator-dependent, and require expert interpretation. DiaNose will fill this gap, aiming to achieve a diagnostic accuracy of >90% at
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101158688 |
| Start date: | 01-05-2024 |
| End date: | 30-04-2027 |
| Total budget - Public funding: | 2 499 875,00 Euro - 2 499 875,00 Euro |
Cordis data
Original description
The analysis of volatile organic compounds (VOCs) in exhaled breath with nano sensors has great potential to transform healthcare, with accurate, inexpensive, real-time diagnostics. However, attempts to implement this strategy have failed to reach clinical deployment. Firstly, many efforts try to identify the complex mixture of VOCs associated with disease, which is a long and expensive process. Secondly, commercially available sensors require high operating temperatures and have low sensitivity to breath VOCs. NaNose Medical has overcome these limitations through DiaNose, an easy to use, hand-held diagnostics device with potential applicability in >20 different diseases. Instead of identifying individual VOCs, DiaNose deploys an array of patented cross-reactive sensors delivering a chemical signature of breath that can be classified as healthy or diseased through artificial intelligence. Our initial alpha prototype focuses on a key clinical indication: Non-Alcoholic Fatty Liver Disease (NAFLD): with a global prevalence of 30%, it is the leading cause of liver related morbidity, generating an annual burden in Europe of > €35 billion and a further €200 billion of societal costs. Crucially, NAFLD diagnostics present key limitations: liver biopsies are expensive, invasive and subject to sampling error, and non-invasive alternatives lack precision, are operator-dependent, and require expert interpretation. DiaNose will fill this gap, aiming to achieve a diagnostic accuracy of >90% atStatus
SIGNEDCall topic
HORIZON-EIC-2023-TRANSITIONCHALLENGES-01Update Date
21-11-2024
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
